乳腺鳞状细胞癌与浸润性导管癌患者按生物学亚型的生存率比较：日本国家临床数据库-乳腺癌登记处的配对分析。

Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese national clinical database-breast cancer registry.

作者信息

Ogita Mami, Kumamaru Hiraku, Kubo Makoto, Kinukawa Naoko, Niikura Naoki, Saji Shigehira, Toi Masakazu

机构信息

Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; Committee of Breast Cancer Registry and Data Science, 3-8-16, Nihonbashi, Chuo-ku, Tokyo, 103-0027, Japan.

出版信息

Breast. 2025 Aug 27;83:104567. doi: 10.1016/j.breast.2025.104567.

DOI:10.1016/j.breast.2025.104567

PMID:40896954

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12433503/

Abstract

PURPOSE

Owing to the rarity of primary squamous cell carcinoma (SCC) of the breast, the prognosis of SCC remains uncertain. We aimed to investigate the clinical features and prognosis of breast SCC by subtype.

METHODS

A total of 350,977 patients with breast SCC or invasive ductal carcinoma (IDC) were identified from the National Clinical Database-Breast Cancer Registry from 2004 to 2014. SCC and IDC patients with triple-negative and luminal subtypes were matched 1:1 via exact matching. Overall survival (OS), breast cancer-specific survival (BCSS), and recurrence-free survival (RFS) were compared between patients with SCC and those with IDC. In-field area recurrence was analyzed among patients who received adjuvant radiotherapy.

RESULTS

The study included 452 SCC patients and 182,707 IDC patients. SCC patients were more likely than IDC patients to have advanced-stage disease. The crude 10-year OS, BCSS, and RFS were 70 %, 80 %, and 66 % for patients with SCC, and 88 %, 93 %, and 81 % for patients with IDC, respectively. After 204 patients with the triple-negative subtype and 68 patients with the luminal subtype in each group were matched, the 10-year BCSS was significantly worse for SCC (76.7 %) than for IDC (85.5 %) within the triple-negative subtype. There were no differences in OS, BCSS, or RFS for the luminal subtype. The rates of in-field area recurrence were similar between patients with SCC and those with IDC with either the triple-negative subtype or the luminal subtype.

CONCLUSIONS

Within the triple-negative subtype, SCC histology was associated with a significantly worse prognosis than IDC.

摘要

目的

由于原发性乳腺鳞状细胞癌（SCC）罕见，SCC的预后仍不明确。我们旨在按亚型研究乳腺SCC的临床特征和预后。

方法

从2004年至2014年的国家临床数据库-乳腺癌登记处中识别出总共350977例乳腺SCC或浸润性导管癌（IDC）患者。三阴型和管腔型亚型的SCC和IDC患者通过精确匹配按1:1配对。比较SCC患者和IDC患者的总生存期（OS）、乳腺癌特异性生存期（BCSS）和无复发生存期（RFS）。对接受辅助放疗的患者分析野内区域复发情况。

结果

该研究纳入了452例SCC患者和182707例IDC患者。SCC患者比IDC患者更易出现晚期疾病。SCC患者的10年粗OS、BCSS和RFS分别为70%、80%和66%，IDC患者分别为88%、93%和81%。每组中204例三阴型亚型患者和68例管腔型亚型患者匹配后，三阴型亚型内SCC患者的10年BCSS（76.7%）明显差于IDC患者（85.5%）。管腔型亚型的OS、BCSS或RFS无差异。三阴型或管腔型亚型的SCC患者和IDC患者的野内区域复发率相似。